Company / Operating Cash Flow per Share
Gilead Sciences Operating Cash Flow per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow per Share
$8.04
FY2025
5-year range
$6.51 / $9.13
FY2021-FY2025
Trend
-7.5%
vs FY2024
Sector context
#14 of 212
Health Care
What the data says
Among 212 Health Care companies, Gilead Sciences is in the top 7% for operating cash flow per share. Operating Cash Flow per Share has fluctuated over the past 10 years, ranging from $6.45 in FY2020 to $16.22 in FY2017.
Based on SEC 10-K filings.
8.04 in FY2025 with a 5-year CAGR of +4.5%. Top quartile in the Health Care sector.
Declined from $9.13 to $8.04 over the past 2 years.
Health Care sector context is included.
Operating Cash Flow per Share over time
Growth rates
- 3-Year CAGR
- +7.3%
- 5-Year CAGR
- +4.5%
- 10-Year CAGR
- -
Sector benchmark
+154.6% above sector average
Key checks
Key Insights
- In FY2025, operating cash flow per share decreased 7.5% year-over-year.
- Ranks #14 out of 212 companies in the Health Care sector.
- Peak operating cash flow per share was recorded in FY2017.
- Lowest operating cash flow per share in the period was in FY2020.
Company context
Key Data Points
- Strong profit margin: 27.9%
- Strong return on equity: 37.6%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash Flow per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $8.04 | -7.5% |
| FY2024 | $8.69 | -4.8% |
| FY2023 | $9.13 | +40.2% |
| FY2022 | $6.51 | -10.7% |
| FY2021 | $7.29 | +13.0% |
| FY2020 | $6.45 | -30.5% |
| FY2019 | $9.28 | -28.8% |
| FY2018 | $13.03 | -19.7% |
| FY2017 | $16.22 | +80.0% |
| FY2016 | $9.01 | -36.4% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026